No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment

Hitoshi Takahashi; Keizo Yoshida; Kenich Ito; Kazuhiro Sato; Mitsuhiro Kamata; Hisashi Higuchi; Tetsuo Shimizu; Kunihiko Ito; Kazuyuki Inoue; Takehiko Tezuka; Toshio Suzuki; Tadashi Ohkubo; Kazunobu Sugawara

doi:10.1016/s0924-977x(02)00056-1

No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment

Eur Neuropsychopharmacol. 2002 Oct;12(5):477-81. doi: 10.1016/s0924-977x(02)00056-1.

Authors

Hitoshi Takahashi¹, Keizo Yoshida, Kenich Ito, Kazuhiro Sato, Mitsuhiro Kamata, Hisashi Higuchi, Tetsuo Shimizu, Kunihiko Ito, Kazuyuki Inoue, Takehiko Tezuka, Toshio Suzuki, Tadashi Ohkubo, Kazunobu Sugawara

Affiliation

¹ Department of Psychiatry, Akita University School of Medicine, 1-1-1, Hondo, 010-8543, Akita, Japan. hito.takahashi@hotmail.com

PMID: 12208565
DOI: 10.1016/s0924-977x(02)00056-1

Abstract

We investigated the association between serotonergic polymorphisms and incidence of nausea, which is the most frequent side-effect of selective serotonin reuptake inhibiters (SSRIs), in 66 patients treated with fluvoxamine in a protocolized-dosing method. We focused on three polymorphisms of serotonin (5-HT) neuronal systems such as 5-HT transporter (5-HTT) gene-linked polymorphic region (5-HTTLPR), a variable number of tandem repeat (VNTR) polymorphism in the second intron of the 5-HTT gene (STin2) and tryptophan hydroxylase (TPH) gene polymorphism in intron 7 (TPH-A218C), which have been reported to possess positive association with treatment response to SSRIs. In addition to this, the relationship between development of nausea and treatment response was also analyzed. Results suggested that these three polymorphisms did not affect the development of fluvoxamine-induced nausea, and that incidence of nausea was not a phenomenon that predicts the treatment response to fluvoxamine.

Publication types

Clinical Trial

MeSH terms

Adult
Aged
Antidepressive Agents, Second-Generation / adverse effects*
Antidepressive Agents, Second-Generation / blood
Antidepressive Agents, Second-Generation / therapeutic use
Carrier Proteins / genetics*
Chi-Square Distribution
Depressive Disorder, Major / drug therapy
Depressive Disorder, Major / genetics
Female
Fluvoxamine / adverse effects*
Fluvoxamine / blood
Fluvoxamine / therapeutic use
Gene Frequency
Genotype
Humans
Introns / genetics
Linkage Disequilibrium
Male
Membrane Glycoproteins / genetics*
Membrane Transport Proteins*
Middle Aged
Minisatellite Repeats / genetics
Nausea / chemically induced*
Nerve Tissue Proteins*
Polymorphism, Genetic
Serotonin Plasma Membrane Transport Proteins
Tryptophan Hydroxylase / genetics

Substances

Antidepressive Agents, Second-Generation
Carrier Proteins
Membrane Glycoproteins
Membrane Transport Proteins
Nerve Tissue Proteins
SLC6A4 protein, human
Serotonin Plasma Membrane Transport Proteins
Tryptophan Hydroxylase
Fluvoxamine